| 发明名称 | HSV-1 epitopes and methods for using same | ||
| 摘要 | The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | ||
| 申请公布号 | US9328144(B2) | 申请公布日期 | 2016.05.03 |
| 申请号 | US201313892185 | 申请日期 | 2013.05.10 |
| 申请人 | UNIVERSITY OF WASHINGTON;Erasmus University Medical Center Rotterdam (Erasmus MC) | 发明人 | Koelle David M.;Verjans George M. G. M. |
| 分类号 | C07K14/005;A61K39/12;A61K39/245;A61K35/12;A61K39/00 | 主分类号 | C07K14/005 |
| 代理机构 | canady + lortz LLP | 代理人 | Canady Karen S.;canady + lortz LLP |
| 主权项 | 1. A fusion protein, comprising a heterologous polypeptide fused to an immunogenic portion of HSV-1VP16 (SEQ ID NO:1), wherein said portion consists of amino acids 64-160, 90-99, 141-240, 191-203, 215-227, 218-320, 219-230, 479-489, 479-488, 480-488 or 477-490 of VP16 (SEQ ID NO: 1) and up to 50 amino acids of adjacent sequence of the original protein of SEQ ID NO:1, or a polynucleotide encoding said fusion protein. | ||
| 地址 | Seattle WA US | ||